Navigating the Future of Clinical Trial Shipping

Niall Balfour, Chief Executive Officer at Tower Cold Chain, explores how to achieve optimum protection for clinical trial shipments.

The global clinical trials market is anticipated to approach nearly $100 billion by 2030, as per recent forecasts from Fortune Business Insights. The UK, in response to this growth and influenced by regulatory measures like those introduced by the MHRA, has undergone a substantial overhaul in trial regulation, marking the most significant change in over two decades and leading to a faster approval process for clinical trials.

Such acceleration of trial approvals underscores the importance of reliable and efficient temperature-controlled solutions during clinical trial shipping. And, given the high value, perishable nature, and susceptibility to temperature changes and microbial contamination of clinical trial products, maintaining an ambient and secure environment during transportation is crucial.

In this context, it becomes vital to invest in a clinical trial packaging solution, tailored specifically to smaller shipments with an optimal packaging-to-payload ratio which is still able to deal with challenging supply chains.

For full article please visit: https://manufacturingchemist.com/navigating-the-future-of-clinical-trial-shipping